drug_type
RELEVANT_DRUG
intervention_type
CAR-T Therapy
drug_description
Autologous T cells engineered with chimeric antigen receptors (typically targeting CD19/CD20) to redirect T-cell cytotoxicity against malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor (typically targeting B‑cell antigens such as CD19 or CD20). CAR binding to the tumor antigen triggers CD3ζ and costimulatory signaling (e.g., CD28 or 4‑1BB), leading to T‑cell activation, proliferation, cytokine release, and targeted cytotoxic killing of malignant B cells independent of MHC.
drug_name
CAR-T cell therapy
nct_id_drug_ref
NCT06796517